Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Summary

The purpose of this study is to measure the ability of erlotinib to effectively treat recurrent lung cancer which carries an EGFR mutation lung cancer after prior treatment with erlotinib or gefitinib received in the post-surgical or post-radiation setting.

Timeline

Start

2010-08

Primary completion

2012-01

Completion

2012-01

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of accrual”

Drugs

Indications